ATE555082T1 - Salz von aliskiren mit orotsäure - Google Patents

Salz von aliskiren mit orotsäure

Info

Publication number
ATE555082T1
ATE555082T1 AT07819654T AT07819654T ATE555082T1 AT E555082 T1 ATE555082 T1 AT E555082T1 AT 07819654 T AT07819654 T AT 07819654T AT 07819654 T AT07819654 T AT 07819654T AT E555082 T1 ATE555082 T1 AT E555082T1
Authority
AT
Austria
Prior art keywords
aliskiren
salt
orotic acid
orotic
acid
Prior art date
Application number
AT07819654T
Other languages
English (en)
Inventor
Jean-Louis Reber
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38002048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE555082(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE555082T1 publication Critical patent/ATE555082T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07819654T 2006-11-09 2007-11-07 Salz von aliskiren mit orotsäure ATE555082T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06123758 2006-11-09
PCT/EP2007/009644 WO2008055669A1 (en) 2006-11-09 2007-11-07 Salt of aliskiren with orotic acid

Publications (1)

Publication Number Publication Date
ATE555082T1 true ATE555082T1 (de) 2012-05-15

Family

ID=38002048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07819654T ATE555082T1 (de) 2006-11-09 2007-11-07 Salz von aliskiren mit orotsäure

Country Status (16)

Country Link
US (1) US20100130616A1 (de)
EP (1) EP2089356B1 (de)
JP (1) JP2010509254A (de)
KR (1) KR20090081010A (de)
CN (1) CN101528672A (de)
AR (1) AR063597A1 (de)
AT (1) ATE555082T1 (de)
AU (1) AU2007316878B2 (de)
BR (1) BRPI0718701A2 (de)
CA (1) CA2665073A1 (de)
CL (1) CL2007003216A1 (de)
MX (1) MX2009004628A (de)
PE (1) PE20081167A1 (de)
RU (1) RU2456267C2 (de)
TW (1) TW200838836A (de)
WO (1) WO2008055669A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100076996A (ko) * 2007-09-28 2010-07-06 노파르티스 아게 알리스키렌의 생약 제형
CA2724746A1 (en) * 2008-05-23 2009-11-26 Teva Pharmaceuticals Industries Ltd. Aliskiren monofumarate and processes for preparation thereof
EP2393489B1 (de) 2009-02-05 2014-10-08 Krka, tovarna zdravil, d.d., Novo mesto Flüssigkeitsaktiviertes Granulationsverfahren
CN102046162A (zh) 2009-02-05 2011-05-04 特瓦制药工业有限公司 阿利吉仑化合物的固态形式

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US6730798B2 (en) * 2000-07-05 2004-05-04 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
KR101184797B1 (ko) * 2003-09-04 2012-09-20 세파론, 인코포레이티드 모다피닐 조성물
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds

Also Published As

Publication number Publication date
JP2010509254A (ja) 2010-03-25
RU2456267C2 (ru) 2012-07-20
TW200838836A (en) 2008-10-01
PE20081167A1 (es) 2008-10-03
BRPI0718701A2 (pt) 2013-12-31
WO2008055669A1 (en) 2008-05-15
CL2007003216A1 (es) 2008-06-13
KR20090081010A (ko) 2009-07-27
RU2009121646A (ru) 2010-12-20
AU2007316878B2 (en) 2011-07-14
MX2009004628A (es) 2009-05-15
EP2089356B1 (de) 2012-04-25
AU2007316878A1 (en) 2008-05-15
US20100130616A1 (en) 2010-05-27
CA2665073A1 (en) 2008-05-15
EP2089356A1 (de) 2009-08-19
AR063597A1 (es) 2009-02-04
CN101528672A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
CY2021030I1 (el) Νεο οξινο θειικο αλας
FIC20200046I1 (fi) Alpelisibi tai sen suola
HUS2100007I1 (hu) Filgotinib vagy sója
EP2207899A4 (de) Zusammenbau grosser nukleinsäuren
DK2206707T3 (da) Azolcarboxamidforbindelse eller salt deraf
DK2101570T3 (da) Tannatsalt af rasagilin
PL3699162T3 (pl) Heterodimery kwasu glutaminowego
BRPI0915763A2 (pt) divisão térmica do sal de carboxilatos de amônio
DE602007009238D1 (de) Biplanare elektrode mit sperr-gates
DK2129797T3 (da) Nukleinsyrepåvisning
PL3590949T3 (pl) Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
ATE510923T1 (de) Nukleinsäure
DK2220021T3 (da) Fremgangsmåde til fremstilling af terephtalsyre
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
FR2987498B1 (fr) Sulfates utiles comme materiaux d'electrode
DK2352930T3 (da) Asymmetrisk lejring
BRPI0921038A2 (pt) ácido naftilacéticos
ATE491455T1 (de) Konzentrierte methotrexat-lösungen
EP2264167A4 (de) Doppelsträngige lipid-modifizierte rna mit hohem rna-interferenzeffekt
ATE549325T1 (de) 3-amino-1,2-benzisothiazol-verbindungen zur bekämpfung von tierpest ii
ATE478730T1 (de) Metallsalz-nanogel enthaltende polymere
EP2315757A4 (de) Herstellung von hydroxymethylfurfual
BRPI0815332A2 (pt) Composto de ácido fenilacético
EP2062902A4 (de) Lithiumsalz
DE602006015909D1 (de) Kristalline valnemulinsalze mit organischen säuren